Research programme: heparosan-based conjugates - Caisson Biotech/Novo Nordisk

Drug Profile

Research programme: heparosan-based conjugates - Caisson Biotech/Novo Nordisk

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Caisson Biotech; Novo Nordisk
  • Class Amino sugars; Drug conjugates; Glucuronic acids; Insulins; Pancreatic hormones; Polysaccharides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus
  • Research Haemophilia

Most Recent Events

  • 24 Aug 2016 Caisson Biotech has patent protection for Factor VIIa HEPtune® Conjugate in USA
  • 24 Aug 2016 Pharmacodynamics data from research studies in Haemophilia released by Caisson Biotech
  • 11 Mar 2014 Preclinical trials in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top